ATE478089T1 - Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen - Google Patents
Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennenInfo
- Publication number
- ATE478089T1 ATE478089T1 AT02751526T AT02751526T ATE478089T1 AT E478089 T1 ATE478089 T1 AT E478089T1 AT 02751526 T AT02751526 T AT 02751526T AT 02751526 T AT02751526 T AT 02751526T AT E478089 T1 ATE478089 T1 AT E478089T1
- Authority
- AT
- Austria
- Prior art keywords
- epitope
- arg
- amino acid
- acid residue
- residue selected
- Prior art date
Links
- 230000003472 neutralizing effect Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 6
- 101710104895 DNA replication protein 17 Proteins 0.000 abstract 1
- 102100037593 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta Human genes 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000002054 inoculum Substances 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001TO000795A ITTO20010795A1 (it) | 2001-08-07 | 2001-08-07 | Polipeptide isolato basato sulla sequenza della proteina p17 utile come vaccino anti-hiv. |
| ITTO20011042 ITTO20011042A1 (it) | 2001-11-02 | 2001-11-02 | Polipeptidi isolati basati sulla sequenza della proteina p17 di hiv utili come vaccino anti-hiv. |
| PCT/IB2002/003093 WO2003016337A1 (en) | 2001-08-07 | 2002-08-05 | Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478089T1 true ATE478089T1 (de) | 2010-09-15 |
Family
ID=26332884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751526T ATE478089T1 (de) | 2001-08-07 | 2002-08-05 | Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7541036B2 (de) |
| EP (1) | EP1417222B1 (de) |
| AT (1) | ATE478089T1 (de) |
| DE (1) | DE60237373D1 (de) |
| DK (1) | DK1417222T3 (de) |
| PT (1) | PT1417222E (de) |
| RU (1) | RU2337922C9 (de) |
| WO (1) | WO2003016337A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20020286A1 (it) * | 2002-03-29 | 2003-09-29 | Medestea Int Spa | Uso della proteina p17 isolata per la preparazione di un medicamento atto ad inibire gli effetti immunostimolanti che la proteina prodotta d |
| MXPA05011997A (es) * | 2005-11-08 | 2007-05-07 | Univ Mexico Nacional Autonoma | Vacuna intranasal contra la enfermedad ocasionada por escherichia coli enterotoxigenica. |
| WO2008157483A2 (en) * | 2007-06-14 | 2008-12-24 | The Research Foundation Of State University Of New York | Polypeptides and methods of use |
| ITTO20080027A1 (it) * | 2008-01-15 | 2009-07-16 | Medestea Res & Production S P A | Forma troncata della proteina p17 di hiv. |
| RU2412946C1 (ru) * | 2009-11-03 | 2011-02-27 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛ К БЕЛКУ р17 ВИЧ |
| IT1401359B1 (it) * | 2010-03-31 | 2013-07-18 | Medestea Res & Production S P A | Anticorpo monoclonale diretto contro la proteina p17 di hiv, atto a neutralizzare il legame fra la proteina p17 e il recettore della proteina p17 (p17r) |
| RU2475264C2 (ru) * | 2010-12-29 | 2013-02-20 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства | Вакцина против вич/спид |
| US10729741B2 (en) | 2017-03-27 | 2020-08-04 | Neomatrix Therapeutics Inc. | Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury |
| CA3135743A1 (en) | 2018-05-09 | 2019-11-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Method for electronic detection and quantification of antibodies |
| AU2019269615B2 (en) | 2018-05-17 | 2023-04-06 | Recognition AnalytiX, Inc. | Device, system and method for direct electrical measurement of enzyme activity |
| US12351855B2 (en) | 2019-01-30 | 2025-07-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Bioelectronic circuits, systems and methods for preparing and using them |
| RU2727673C1 (ru) * | 2019-08-09 | 2020-07-22 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Антитела против белка р17 ВИЧ-1 субтипа А |
| US11913070B2 (en) | 2020-02-28 | 2024-02-27 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for sequencing biopolymers |
| CN115552030A (zh) | 2020-04-17 | 2022-12-30 | 代表亚利桑那大学的亚利桑那校董事会 | 单分子电子序列检测器及其使用方法 |
| IL297732A (en) | 2020-04-30 | 2022-12-01 | Univ Arizona State | Methods for sequencing biopolymers |
| US12276653B2 (en) | 2020-05-29 | 2025-04-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Bioelectronic devices with programmable adaptors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988009670A1 (en) * | 1987-06-10 | 1988-12-15 | The Immune Response Corporation, Inc. | Prevention and treatment of retroviral disease |
| US5185147A (en) * | 1988-08-19 | 1993-02-09 | Cellular Products, Inc. | Short polypeptide sequences useful in the production and detection of antibodies against human immunodeficiency virus |
| NZ235538A (en) * | 1989-10-12 | 1992-06-25 | Viral Technologies Inc | Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera |
| US6093400A (en) * | 1996-08-09 | 2000-07-25 | Cel Sci Corporation | Modified HGP-30 peptides, conjugates, compositions and methods of use |
-
2002
- 2002-08-05 WO PCT/IB2002/003093 patent/WO2003016337A1/en not_active Ceased
- 2002-08-05 EP EP02751526A patent/EP1417222B1/de not_active Expired - Lifetime
- 2002-08-05 PT PT02751526T patent/PT1417222E/pt unknown
- 2002-08-05 AT AT02751526T patent/ATE478089T1/de not_active IP Right Cessation
- 2002-08-05 DE DE60237373T patent/DE60237373D1/de not_active Expired - Lifetime
- 2002-08-05 RU RU2004106618/13A patent/RU2337922C9/ru active
- 2002-08-05 DK DK02751526.1T patent/DK1417222T3/da active
- 2002-08-05 US US10/485,980 patent/US7541036B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040249124A1 (en) | 2004-12-09 |
| DK1417222T3 (da) | 2010-12-13 |
| RU2337922C2 (ru) | 2008-11-10 |
| EP1417222A1 (de) | 2004-05-12 |
| WO2003016337A1 (en) | 2003-02-27 |
| EP1417222B1 (de) | 2010-08-18 |
| RU2004106618A (ru) | 2005-07-10 |
| RU2337922C9 (ru) | 2009-02-10 |
| US7541036B2 (en) | 2009-06-02 |
| DE60237373D1 (de) | 2010-09-30 |
| PT1417222E (pt) | 2010-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478089T1 (de) | Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen | |
| RU2010116278A (ru) | Модифицированная константная область антитела | |
| DE69435075D1 (de) | , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten | |
| PL363071A1 (pl) | Sposoby i kompozycje dla zmniejszenia replikacji HIV-1 | |
| PE20212075A1 (es) | PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO | |
| JP2002206000A5 (de) | ||
| EA199800046A1 (ru) | Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента | |
| AU2018383708B2 (en) | Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| ATE488249T1 (de) | Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung | |
| Xin et al. | Total chemical synthesis of murine ISG15 and an activity-based probe with physiological binding properties | |
| Muguruma et al. | Kinetics-based structural requirements of human immunoglobulin G binding peptides | |
| BR0309491A (pt) | Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes | |
| ATE177843T1 (de) | Peptomere mit erhöhter immunogenizität | |
| DE69231705D1 (de) | Gag-Env Fusion-Antigen aus HIV | |
| Spetzler et al. | A novel strategy for the synthesis of the cysteine‐rich protective antigen of the malaria merozoite surface protein (MSP‐1) Knowledge‐based strategy for disulfide formation | |
| JP2019525764A5 (de) | ||
| Shiakolas et al. | Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions | |
| ATE521626T1 (de) | Fusionsprotein zur inhibierung von gebärmutterhalskrebs | |
| US20070274997A1 (en) | Compositions and Methods for Herpes Simplex Prophylaxis and Treatment | |
| Chakraborty et al. | NMR structural analysis of a peptide mimic of the bridging sheet of HIV-1 gp120 in methanol and water | |
| Kajiwara et al. | Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group | |
| JP4568842B2 (ja) | 熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法 | |
| Devadas et al. | Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection | |
| WO2004056316A3 (en) | Vaccines against hiv-1 tat protein to generate neutralizing antibodies | |
| Huang et al. | A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |